There has been vocal criticism among some in the Type 1 diabetes community that the 670G is not automated enough to be considered an artificial pancreas. For example, users of the pump system will still have to bolus for meals. Dr. Kowalski said that there is still more work to be done on developing the […]
The US Food and Drug Administration (FDA) approved Abbott’s FreeStyle Libre Pro on September 28 after more than a year of review. The professional continuous glucose monitoring (CGM) system will be made available to US healthcare providers later in Fall 2016.
The results of the clinical study, carried out by American and Italian researchers, focused on middle-aged patients treated with insulin pump therapy. They showed a variety of health benefits for those who took part in aerobic exercise, including improved metabolic control, reduced insulin requirements and less hyperglycemic events.
Every once in a while, a new glucose meter is introduced that really “steps outside the box” and offers something unique. That seems to be the case with the newest meter from Roche Diabetes Care, Accu-Chek Guide, offering some great practical features from tweaks to make carrying and using test strips easier, to improved lighting […]
A new clinical trial is testing a study drug that could help the T2D community eliminate a daily injection: Key Inclusion / Exclusion Criteria: – Are between 18 and 80 years old – Have a diagnosis of type 2 diabetes – Are taking both metformin and liraglutide (Victoza) – Have a BMI (body mass index) […]
Industry-funded researchers say they’ve developed a way to improve the accuracy of a standard diabetes test. “We think our approach will enable many patients and their doctors to do a better job controlling blood sugar levels and reduce the long-term risks of heart attack, stroke, blindness and kidney failure” associated with diabetes, said Dr. John […]
New research says there are better ways to inject insulin with a syringe, as well as manage infusion sites, to get the most out of your insulin and improve diabetes care. It was the most comprehensive gathering of experts convened to examine the ways in which insulin is physically introduced to the body through needles […]
Clinton has made drug price control more of a central issue in her campaign (although it should be said that neither candidate has put the issue on the front burner). For this article, we will focus on her proposal, and what it’s chances are of creating reform.
Last month, a major scientific journal published an unprecedented three papers from the congress, including “New Insulin Delivery Recommendations” from the 183 doctors, nurses, educators, and conference attendees in Rome. The publications are based on results of what is probably the largest survey ever done concerning insulin injection technique in more than 13,000 insulin-injecting people […]
Curious what’s coming? Read on for a summary of the insulin delivery and glucose monitoring devices expected to launch in the US by mid-2017 or earlier, based on the most recent company timelines (listed chronologically). This list is not fully comprehensive, but does cover the major device launches expected.
In June 2016, JDRF and MannKind announced a research and clinical trial collaboration which will focus upon Afrezza’s safety and effectiveness for pediatric use. This will help Mannkind fulfill commitments the company has made to the FDA to do more testing of the product.
No sooner did news break that the FDA had approved the Medtronic 670G did debate start over whether it deserved to be labeled an artificial pancreas. I wanted to provide my thoughts on why as the editorial director of a diabetes news publication, I felt comfortable using the term for this hybrid automated pump-and-CGM system.
A novel treatment meant to stop Type 1 diabetes by increasing the number of T cells in the body is being given special attention by the FDA. The treatment, called CLBS03, has recently been granted Fast Track status by federal regulators, a designation which speeds up the approval process.
The device — Medtronic’s MiniMed 670G — is what’s known as a hybrid closed-loop system. That means it monitors blood sugar and then delivers necessary background (also known as basal) insulin doses. The device will also shut off when blood sugar levels drop too low.
Novo Nordisk voluntarily recalled six batches of its GlucaGen HypoKit (glucagon for injection) on September 9, 2016. Two reports out of Europe detailed malfunction of needles on the syringe containing Sterile Water for Injection (SWFI) – an essential component of the kit.
In his book, Think Like A Pancreas: A Practical Guide to Managing Diabetes With Insulin, certified diabetes educator Gary Scheiner devotes a chapter on the basics of insulin pump therapy. While studies show that pump therapy, when done right, leads to better blood sugar control, it’s not for everyone. Scheiner gives a concise pro/con list […]
A1c has limits: it cannot capture other critical outcomes that matter to patients on a daily basis. Low blood sugar (hypoglycemia) can be fatal, and yet, A1c tells us nothing about it. This article unpacks why going beyond A1c is important and shares other ways of measuring diabetes success.
Following the terminated partnership with Sanofi, MannKind has relaunched its ultra-rapid-acting inhaled (needle free) mealtime insulin, Afrezza. Afrezza is an ultra-rapid-acting insulin for people with type 1 and 2 diabetes, peaking in only 16-21 minutes versus about 60-90 minutes for current injected rapid-acting insulins such as Humalog and Novolog .
The FDA has cleared InPen, Companion Medical’s reusable Bluetooth-enabled smart insulin pen and paired Apple iOS smartphone app. A launch is expected in 2017, likely including Android, too.
For the bionic pancreas to win FDA approval, it will need to prove that the novel aspects of the treatment are safe and effective. Recently, a team of researchers at the Massachusetts General Hospital Diabetes Center in Boston conducted a trial that focused exclusively on the automated delivery of glucagon to see if the treatment […]